Nrx pharmaceuticals (nasdaq:nrxp) reports fourth quarter and full year 2023 financial results and provides business update

Four potential near-term milestones, including data from two clinical trials, an nda filing and an upcoming share dividend -- 50% reduction in corporate overhead and 25% reduction in overall net loss in 2023, compared to 2024 with $0.20 per share improvement in negative earnings. additions to working capital of $8 million in q1 2024.
NRXP Ratings Summary
NRXP Quant Ranking